Metis TechBio seals $1.62b global licensing deal with Boulevard Bio

Hong Kong-listed AI-driven drug delivery innovation company Metis TechBio Co Ltd said on Tuesday it had granted Boulevard Bio, an immunotherapy company backed by healthcare investment firm Deerfield Management, exclusive worldwide rights to develop, manufacture and commercialize its experimental cancer immunotherapy candidate MTS-128 in a deal worth up to $1.62 billion.

Raccontata daglobal.chinadaily.com.cn